Please login to the form below

Not currently logged in
Email:
Password:

The Editors blog

An inside look at what’s happening within the pharma industry and across the PMGroup from the PMLiVE editorial team

Resistance's irresistible need

Industry's anti-infective efforts step up a gear

AntibioticsAntimicrobial resistance. It's not, perhaps, a particularly dynamic topic, but it will be a priority one for 2014, at least as far as the EMA is concerned. 

Finalising its 2014 work programme late last year the European regulator made “tackling the issue of antimicrobial resistance and availability of anti-infective treatment options” one of its focus areas for this year.  

The area has gradually been gaining momentum, especially during the last 12 months, beginning in February when EU efforts to combat the issue saw five major pharma firms partner under the auspices of the Innovative Medicines Initiative's (IMI) New Drugs for Bad Bugs programme.  

As bacterial infections grow increasingly resistant to current treatments, leaving doctors with fewer options, individual companies have made progress on researching new antibiotics.  

Cubist looks to be on track to file its new antibiotic later this year after posting positive phase III data in December and AstraZeneca, despite planning to cut back on its anti-infectives research, forged a new partnership in November with Singapore's main research centre.  

As was noted on PMLiVE recently, the discovery of antibacterial drugs was a transformative moment in human history, but increasing resistance demands a global commitment to develop new drugs. Clearly, when antimicrobial resistance still causes 25,000 deaths each year, the need for pharma successes in this area is irresistible.

Article by
Dominic Tyer

editorial director of PMGroup

14th January 2014

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
90TEN Healthcare

90TEN is an award-winning healthcare communications consultancy that puts people at the heart of everything we do. Our Life.Changing. campaigns...

Latest intelligence

Is the pharma business model ready for precision medicine?
Precision medicine promises to revolutionise patient outcomes and reduce costs for industry but is pharma ready for it? Blue Latitude Health co-founder Head of Strategy Fred Bassett explores the challenges...
ABPI2018
The NHS and ABPI at 70: inching closer to the triple win
The NHS and UK pharma’s ABPI both turn 70 this year. After years of transactional relationships, there’s a will to work more closely - but friction on prices and value...
What pharma marketers can learn from behavioural science
Pharma behavioural science and traditional emotional marketing create a powerful mix of techniques that have impact on real lives....

Infographics